• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

8 drug delivery innovations you need to know

February 25, 2021 By Sean Whooley

Lyra Therapeutics’ bioresorbable treatments

Lyra TherapeuticsWatertown, Mass.-based Lyra Therapeutics is looking to make waves in the ear, nose and throat (otolaryngology) disease treatment space with drugs administered through a bioresorbable polymeric matrix.

LYR-210, the company’s therapeutic, is designed to deliver up to six months of continuous anti-inflammatory drug therapy to the sinonasal passages to treat chronic rhinosinusitis (CRS) in those who have not undergone surgery for the disease.

The therapeutic is under development for CRS patients, while Lyra’s XTreo platform is being developed to address other disease areas through precise, consistent and local delivery combined in a single administration.

Comprising XTreo is a biocompatible mesh scaffold to maximize surface area for drug release while maintaining underlying tissue function, as well as an engineered elastomeric matrix to dynamically adapt to target anatomy and a versatile polymer-drug complex to enable tunable drug elution for long-term dosing.

In December 2020, Lyra announced positive topline results for its LANTERN Phase 2 study of LYR-210 for the treatment of CRS, including statistically significant improvement in a composite score of the four cardinal symptoms of CRS compared to control.

Next>>

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9

Filed Under: Auto-injectors, Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Hydrogels, Otolaryngology Ear, Nose & Throat, Pharmaceuticals, Research & Development, Respiratory, Technology Tagged With: dyvebioscience, Enable Injections, evoxtherapeutics, Inovio Pharmaceuticals, Johns Hopkins, Lyra Therapeutics, Medtronic, Tandem Diabetes Care, Teva, Teva Pharmaceuticals, Teva Respiratory

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS